$815 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 95 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 27.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALT | Sell | ALTIMMUNE INC | $33,208,000 | -21.2% | 2,600,450 | -27.8% | 4.07% | -36.3% |
| ITCI | Sell | INTRA-CELLULAR THERAPIES INC | $29,779,000 | -25.5% | 640,000 | -8.6% | 3.65% | -39.8% |
| BCAB | Sell | BIOATLA INC | $15,146,000 | +57.6% | 1,967,051 | -41.7% | 1.86% | +27.3% |
| VERU | Sell | VERU INC | $12,672,000 | -75.8% | 1,100,000 | -76.2% | 1.55% | -80.4% |
| GLPG | Sell | GALAPAGOS NVspon adr | $9,592,000 | -31.2% | 224,950 | -10.0% | 1.18% | -44.4% |
| GNFT | Sell | GENFIT S Aads | $4,371,000 | +7.6% | 1,197,522 | -5.1% | 0.54% | -13.0% |
| BNTX | Sell | BIONTECH SEsponsored ads | $4,046,000 | -32.2% | 30,000 | -25.0% | 0.50% | -45.2% |
| BLU | Sell | BELLUS HEALTH INC NEW | $2,112,000 | -61.9% | 200,000 | -66.7% | 0.26% | -69.2% |
| Sell | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $2,010,000 | +20.0% | 259,054 | -18.8% | 0.25% | -3.1% | |
| Sell | TSCAN THERAPEUTICS INC | $1,702,000 | -27.6% | 557,915 | -25.4% | 0.21% | -41.5% | |
| Sell | INSPIRATO INCORPORATED | $1,445,000 | -90.1% | 612,345 | -80.6% | 0.18% | -92.0% | |
| Sell | TRITIUM DCFC LIMITEDordinary shares | $1,276,000 | -58.1% | 400,000 | -20.0% | 0.16% | -66.2% | |
| Sell | INSPIRATO INCORPORATED*w exp 02/11/2027 | $88,000 | -88.4% | 365,000 | -68.8% | 0.01% | -90.4% | |
| Exit | ROIVANT SCIENCES LTD | $0 | – | -101,404 | -100.0% | -0.06% | – | |
| RVPH | Exit | REVIVA PHARMACEUTCLS HLDGS I | $0 | – | -1,200,000 | -100.0% | -0.20% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -468,750 | -100.0% | -0.32% | – | |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -3,301,709 | -100.0% | -0.50% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -9,607,934 | -100.0% | -4.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.